I must admit I walked away from the meeting feeling positive but not over the moon. I would have liked pricing and orders but understand that with everything that has happened (opes) and with the process that needs to be put in place tax wise this takes time. There was also talk at the start of the meeting about the possibility of an independent director coming on board. Perhaps someone else who was there can elaborate on this. A new company will be formed to hold the scientists shares (that will need share holders approval) but those shares will be performance based so I have no problem with that. A new share registry would be out by 30Sept and most of if not all of the 65million shares ANZ sold went to friendlies, that was confirmed. There was talk that we will be receiving revenue in 2009 from Ropren. It was also strongly stressed to us that Ropren is eagerly wanted by the hospitals and that SLA is VERY IMPORTANT to Russia. The New Zealand sales will be small but very important I believe and as already stated it'll be $3800 for one course of Ropren. Can't think of anything else but will say the future looks bright for us but it would have been nice for concrete info about pricing and orders. Not long now but some will say yeah yeah heard it all before. We will see today what the market thought of the meeting.
SLA Price at posting:
67.3¢ Sentiment: Buy Disclosure: Held
